Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Partow Kebriaei

Showing results (41-50 of 346) with videos related to

Pageof 35
Sort By:
British Journal of Clinical Pharmacology|May 29, 2020
Chimeric antigen receptor T-cell therapy toxicitiesUri Greenbaum, Partow Kebriaei, Samer A Srour, et al.
Journal of Biopharmaceutical Statistics|October 19, 2012
Bayesian continual reassessment method for dose-finding trials infusing T cells with limited sample sizeYuan Ji, Lei Feng, Ping Liu, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 12, 2013
The impact of pre-transplant valganciclovir on early cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantationKaci Wilhelm, Roy Chemaly, Rima Saliba, et al.
Journal of Geriatric Oncology|May 20, 2014
Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidatesHolly M Holmes, Jude K A Des Bordes, Partow Kebriaei, et al.
Clinical Case Reports|September 28, 2020
Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD-19 chimeric antigen receptor T-cell therapyFrancesco Paolo Tambaro, Sajad Khazal, Cesar Nunez, et al.
Cancer|June 15, 2007
Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicityElias Jabbour, Jorge Cortes, Hagop Kantarjian, et al.
Transplantation and Cellular Therapy|August 17, 2025
The Impact of Isolated HLA-DQB1 Mismatch and Donor Age in Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplant CyclophosphamideRohtesh S Mehta, Yosra M Aljawai, Partow Kebriaei, et al.
American Journal of Hematology|October 18, 2023
Effect of donor age in patients with acute myeloid leukemia undergoing haploidentical hematopoietic cell transplantation vary by conditioning intensity and recipient ageRima M Saliba, Christopher G Kanakry, Shahinaz Gadalla, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 11, 2012
Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized studySimrit Parmar, Gabriela Rondon, Marcos de Lima, et al.
The Lancet. Haematology|January 15, 2016
Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysisShahrukh Hashmi, Mohammad Ahmed, M Hassan Murad, et al.
Pageof 35

Showing results (41-50 of 346) with videos related to

Sort By:
Pageof 35
British Journal of Clinical Pharmacology|May 29, 2020
Chimeric antigen receptor T-cell therapy toxicitiesUri Greenbaum, Partow Kebriaei, Samer A Srour, et al.
Journal of Biopharmaceutical Statistics|October 19, 2012
Bayesian continual reassessment method for dose-finding trials infusing T cells with limited sample sizeYuan Ji, Lei Feng, Ping Liu, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 12, 2013
The impact of pre-transplant valganciclovir on early cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantationKaci Wilhelm, Roy Chemaly, Rima Saliba, et al.
Journal of Geriatric Oncology|May 20, 2014
Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidatesHolly M Holmes, Jude K A Des Bordes, Partow Kebriaei, et al.
Clinical Case Reports|September 28, 2020
Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD-19 chimeric antigen receptor T-cell therapyFrancesco Paolo Tambaro, Sajad Khazal, Cesar Nunez, et al.
Cancer|June 15, 2007
Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicityElias Jabbour, Jorge Cortes, Hagop Kantarjian, et al.
Transplantation and Cellular Therapy|August 17, 2025
The Impact of Isolated HLA-DQB1 Mismatch and Donor Age in Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplant CyclophosphamideRohtesh S Mehta, Yosra M Aljawai, Partow Kebriaei, et al.
American Journal of Hematology|October 18, 2023
Effect of donor age in patients with acute myeloid leukemia undergoing haploidentical hematopoietic cell transplantation vary by conditioning intensity and recipient ageRima M Saliba, Christopher G Kanakry, Shahinaz Gadalla, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 11, 2012
Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized studySimrit Parmar, Gabriela Rondon, Marcos de Lima, et al.
The Lancet. Haematology|January 15, 2016
Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysisShahrukh Hashmi, Mohammad Ahmed, M Hassan Murad, et al.
Pageof 35